Novo Nordisk indicated that only one type of its insulin is in shortage. Manufacturing delays will cause Novo's Fiasp vials ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

This prospective, randomized, controlled, parallel-group study compared the use of pen devices with conventional vials ... insulin pen devices were used: InnoLet and FlexPen (Novo Nordisk).

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.